Gland Pharma Limited — Updates, 30-04-2025: Press Release

Gland Pharma has received USFDA approval for its Latanoprostene Bunod Ophthalmic Solution, 0.024%, targeting open-angle glaucoma and ocular hypertension. As the exclusive First-to-File, the company qualifies for 180 days of generic drug exclusivity. With US sales of approximately USD 171 million in the past year, this approval opens a substantial market opportunity and enhances Gland's standing in the ophthalmic segment.